52%chance
52.0¢ per share
48.0¢ per share
| Price | Shares | Total |
|---|---|---|
| 16¢ | 107.08 | $17.13 |
| 11¢ | 30 | $3.30 |
| 5¢ | 5 | $0.25 |
| 4¢ | 14.45 | $0.58 |
| 3¢ | 338 | $10.14 |
| 2¢ | 812.62 | $16.25 |
| 1¢ | 2,215.34 | $22.15 |
| Price | Shares | Total |
|---|---|---|
| 88¢ | 33.14 | $29.16 |
| 89¢ | 30 | $26.70 |
| 91¢ | 31 | $28.21 |
| 94¢ | 7.71 | $7.25 |
| 95¢ | 20 | $19.00 |
| 96¢ | 61 | $58.56 |
| 97¢ | 65.48 | $63.52 |
| 98¢ | 50 | $49.00 |
| 99¢ | 15.65 | $15.49 |
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.